Sienna Gestion Sells 631 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Key Points

• Sienna Gestion reduced its holdings in Thermo Fisher Scientific Inc. by 6.1%, selling 631 shares in the first quarter, leaving it with around $4.68 million worth of stock.
• Analysts have mixed forecasts for Thermo Fisher, with target prices ranging from $470 to $610 and a consensus rating of "Moderate Buy."
• The company announced a quarterly dividend of $0.43 per share, translating to an annual yield of 0.4%, payable on October 15th.

Sienna Gestion lessened its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 6.1% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,681 shares of the medical research company's stock after selling 631 shares during the period. Sienna Gestion's holdings in Thermo Fisher Scientific were worth $4,683,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Bernard Wealth Management Corp. bought a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth about $25,000. Ameriflex Group Inc. bought a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth about $30,000. IMA Advisory Services Inc. bought a new stake in shares of Thermo Fisher Scientific during the 1st quarter worth about $35,000. Navigoe LLC bought a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth about $37,000. Finally, Smallwood Wealth Investment Management LLC bought a new stake in shares of Thermo Fisher Scientific during the 1st quarter worth about $37,000. Institutional investors own 89.23% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts recently commented on TMO shares. UBS Group lifted their target price on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a "neutral" rating in a report on Thursday, July 24th. Barclays increased their target price on shares of Thermo Fisher Scientific from $450.00 to $490.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 24th. The Goldman Sachs Group set a $610.00 target price on shares of Thermo Fisher Scientific and gave the stock a "buy" rating in a research report on Wednesday, April 23rd. Robert W. Baird increased their target price on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an "outperform" rating in a research report on Thursday, July 24th. Finally, Argus decreased their target price on shares of Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating on the stock in a research report on Tuesday, April 29th. Seven investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $593.00.

Thermo Fisher Scientific Price Performance

TMO stock opened at $485.72 on Thursday. The company has a 50 day simple moving average of $431.32 and a 200 day simple moving average of $462.11. The stock has a market cap of $183.41 billion, a price-to-earnings ratio of 28.09, a P/E/G ratio of 2.55 and a beta of 0.74. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $627.88. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business had revenue of $10.86 billion during the quarter, compared to analysts' expectations of $10.68 billion. During the same period in the prior year, the company earned $5.37 EPS. The firm's quarterly revenue was up 2.9% compared to the same quarter last year. Research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 0.4%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio is 9.95%.

Insider Activity at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $451.82, for a total transaction of $4,518,200.00. Following the completion of the sale, the chief executive officer directly owned 115,174 shares in the company, valued at $52,037,916.68. This represents a 7.99% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction on Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the transaction, the executive vice president directly owned 22,367 shares of the company's stock, valued at $10,735,712.66. This represents a 1.76% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 18,400 shares of company stock valued at $8,345,792. Corporate insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.